To print: Select File and then Print from your browser's menu

Title: Combined Chemotherapy and Radiation for Sarcomas Effective But Toxic: Presented at SSO

"Combined Chemotherapy and Radiation for Sarcomas Effective But Toxic: Presented at SSO"

By Carole Bullock CHICAGO -- March 19, 2008 -- Neoadjuvant chemotherapy plus radiation therapy for high-risk sarcomas, while effective, is a "highly toxic" regimen, researchers said here on March 15 at the Society of Surgical Oncology (SSO) 61st Annual Cancer Symposium. A dosing adjustment is recommended to ensure the effectiveness of this treatment's therapeutic role. "This combined-modality treatment program can be delivered successfully," stated lead author William Kraybill, MD, Professor of Surgery and Vice-Chair of Surgery, University of Missouri, Kansas City, Missouri. "Survival outcomes in these high-risk sarcoma patients were quite impressive, but it is extraordinarily toxic, and a decreased dose and modification of treatment may be needed." Dr. Kraybill reported on a 5-year follow-up of the 2006 Radiation Therapy Oncology Group (RTOG) study that tested 2 therapies: chemotherapy (CT) and radiation therapy (RT). Preoperative CT and all planned CT were completed for 78.1% and 56.3% of patients, respectively. Estimated 5-year rates of disease-free survival were 56.1%, noted Dr. Kraybill. For distant disease-free survival and overall survival, the estimated 5-year rates were 64.1% and 71.2%, respectively. The trial analysed 64 patients with high-grade soft-tissue sarcoma (8 cm in diameter) of the extremities and body wall. Patients were treated with 3 cycles of neoadjuvant CT (mesna, doxorubicin, ifosfamide, and dacarbazine) and preoperative RT (44 Gy administered in split courses), followed by 3 cycles of postoperative CT. After approximately 8 years, 22 patients had died and 42 patients had survived (35 of whom had no recurrence post-treatment). The 5-year rates of local-regional failure (including amputation) and distant metastasis were 22.2% (95% confidence interval [CI], 11.8, 32.6) and 28.1% (95% CI, 17, 39.2). The most common site of metastasis was the lung, and 6 patients experienced a second primary tumour in either the lung, neck, pancreas, or thigh, Dr. Kraybill noted Three patients (4.7%) had grade 5 toxicities (2 myelodysplasia, 1 infection); 12 patients (18.8%) had grade 4 nonhaematologic toxicity. Grade 3 and 2 delayed wound healing occurred in 3.3% and 9.8 % of patients, respectively. Getting around the toxicity issue of this program may require newer radiation technology and less intensive CT for patients, Dr. Kraybill noted. This study was funded by the RTOG. [[Presentation title: Updated Analysis of a Phase II Study of Neoadjuvant Chemotherapy and Radiation Therapy in the Management of High-Risk, High-Grade, Soft Tissue Sarcomas of the Extremities and Body Wall: Radiation Therapy Oncology Group Trial 9514. Abstract 50]

Copyright © 2009 P\S\L Consulting Group Inc. All rights reserved. Republication or redistribution of P\S\L content is expressly prohibited without the prior written consent of P\S\L. P\S\L shall not be liable for any errors, omissions or delays in this content or any other content on its sites, newsletters or other publications, nor for any decisions or actions taken in reliance on such content.